Redundant roles of YES and SRC tyrosine kinases in driving malignant peripheral nerve sheath tumors

This study identifies YES and SRC tyrosine kinases as redundant, essential drivers of malignant peripheral nerve sheath tumors (MPNST), demonstrating that their dual inhibition suppresses tumor growth by rewiring oncogenic signaling and reactivating immune pathways, thereby establishing them as promising therapeutic targets.

The Gist

The Big Picture: A "Double-Engine" Problem in a Deadly Cancer

Imagine Malignant Peripheral Nerve Sheath Tumors (MPNSTs) as a runaway train. It's a very aggressive, hard-to-stop cancer that grows on the nerves. Currently, doctors have very few tools to stop it once it spreads; surgery is often the only option, but the train often comes back.

This paper discovers that this runaway train is powered by two specific engines working together: proteins called YES and SRC.

Here is the twist: These two engines are "redundant." Think of them like a car with two identical engines. If you cut the fuel line to just one, the car keeps driving because the other one takes over. But if you cut the fuel to both at the same time, the car stops dead. The researchers found that to stop this cancer, you have to shut down both engines simultaneously.

---

The Story of the Discovery

1. The Suspects: YES and SRC

Scientists knew that a "master switch" in these cancer cells (called YAP/TAZ) was stuck in the "ON" position, telling the cells to grow non-stop. They also knew that YES and SRC were the hands pushing that switch.

• The Experiment: They tried turning off just YES. The cancer slowed down a little. They tried turning off just SRC. It slowed down a little.
• The Breakthrough: When they turned off both YES and SRC at the same time, the cancer cells basically gave up. They stopped dividing and started dying. It turns out these two proteins are essential "co-pilots" for the cancer's survival.

2. The "Magic Bullet" (Dasatinib)

The researchers tested a drug called Dasatinib (which is already used for some leukemias). This drug acts like a universal wrench that jams both the YES and SRC engines.

• In the Lab: When they added Dasatinib to cancer cells, the cells stopped growing.
• In Mice: They grew tumors in mice. When they treated the mice with Dasatinib, the tumors stopped growing, and the mice lived much longer. It was like hitting the emergency brake on the runaway train.

3. The Surprise: Waking Up the Body's Security System

This is the most exciting part of the paper.

Usually, MPNSTs are "invisible" to the body's immune system. Imagine the cancer cells are wearing invisibility cloaks. They hide their "ID badges" (called MHC Class I) so the body's security guards (T-cells) can't see them to attack.

• The Discovery: When the researchers jammed the YES and SRC engines, the cancer cells didn't just stop growing; they ripped off their invisibility cloaks.
• The Analogy: By stopping these two proteins, the cancer cells suddenly started flashing their ID badges loudly. They also started sending out "SOS" signals (inflammatory signals).
• Why it matters: This turns a "cold" tumor (one the immune system ignores) into a "hot" tumor (one the immune system can see and attack). This suggests that combining this drug with immunotherapy (vaccines or checkpoint inhibitors) could be a game-changer.

4. The "Why" (The Mechanism)

How did they figure this out? They used two high-tech tools:

1. A Transcriptome Map: Like reading the cancer's instruction manual to see which genes were being turned on or off.
2. A Phosphoproteome Map: Like taking a snapshot of all the electrical wires inside the cell to see where the electricity was flowing.

They found that YES and SRC are like the central hub of a city's power grid. When you cut the power to this hub, two things happen:

1. The factories (cell division) shut down.
2. The security cameras (immune system signals) turn on.

5. The Real-World Proof

Finally, the team looked at data from hundreds of human patients. They found that patients with high levels of the YES protein had shorter survival times. This confirms that YES isn't just a lab curiosity; it's a real villain in human MPNSTs.

---

The Takeaway

This paper suggests a new strategy for treating a very difficult cancer:

1. Don't just hit one target: Because YES and SRC are redundant, you must hit both.
2. Two birds, one stone: A drug that blocks these proteins does two things at once: it stops the cancer from growing and makes the cancer visible to the immune system.

In simple terms: The researchers found the "kill switch" for this specific cancer. It's a double switch that, when flipped, not only kills the cancer cells but also wakes up the body's own army to finish the job. This gives hope that we might finally have a way to treat this aggressive disease effectively.

Technical Summary

1. Problem Statement

Malignant Peripheral Nerve Sheath Tumors (MPNSTs) are highly aggressive soft tissue sarcomas, often arising in patients with Neurofibromatosis type 1 (NF1). They are characterized by:

• Poor Prognosis: A 5-year overall survival rate of ~50%, with high rates of recurrence and metastasis.
• Therapeutic Void: No clinically effective systemic therapies or immunotherapies exist for advanced disease.
• Immune Evasion: MPNSTs are "immune-cold" tumors with low T-cell infiltration and downregulated antigen processing/presentation genes, limiting the efficacy of immune checkpoint inhibitors.
• Molecular Complexity: While drivers like NF1, TP53, CDKN2A/B, and PRC2 loss are known, actionable therapeutic targets remain elusive. Recent studies implicate the Hippo-YAP/TAZ pathway, but upstream regulators of this pathway in MPNST are not fully defined.

2. Methodology

The study employed a multi-modal approach combining genetic, pharmacological, transcriptomic, and proteomic techniques:

• Cell Models: Utilized a panel of human MPNST cell lines (S462TY, sNF96.2, sNF02.2) and plexiform neurofibroma lines (ipNF05.5, ipNF95.6).
• Genetic Perturbation:
  • siRNA/shRNA: Transient and inducible (Doxycycline-controlled) knockdown of YES1, SRC, YAP, and TAZ.
  • CRISPR/Cas9: Used to generate double-knockout clones to test functional redundancy.
• Pharmacological Inhibition: Treatment with SFK inhibitors Dasatinib and Ponatinib.
• In Vivo Models:
  • Subcutaneous Xenografts: NSG mice injected with S462TY cells; treated with Doxycycline (for genetic depletion) or Dasatinib.
  • Orthotopic Model: Luciferase-labeled S462TY cells injected directly into the sciatic nerve of NSG mice to mimic clinical presentation; monitored via bioluminescence imaging.
• Omics Analyses:
  • RNA-seq: Bulk sequencing of control vs. YES/SRC-depleted cells to identify transcriptional changes.
  • Phosphotyrosine Proteomics: LC-MS/MS analysis of phosphotyrosine-enriched peptides following genetic depletion (96h) and acute pharmacological inhibition (1h) to map signaling networks.
• Clinical Correlation: Immunohistochemistry (IHC) on a tissue microarray (TMA) of MPNST vs. benign tumors; analysis of public sarcoma transcriptomic datasets (Centre Léon Bérard, TCGA).

3. Key Contributions

• Identification of Redundant Drivers: Established YES and SRC as redundant, essential non-oncogene addictions for MPNST viability.
• Dual Mechanism of Action: Revealed that YES/SRC inhibition not only suppresses oncogenic proliferation pathways but also reactivates anti-tumor immunity by upregulating MHC class I expression.
• Mechanistic Insight: Mapped the specific signaling network connecting SFKs to the Hippo-YAP/TAZ axis and the IFN-JAK-STAT/MHC class I pathway.
• Therapeutic Validation: Demonstrated that dual inhibition (genetic or pharmacological) significantly delays tumor growth and improves survival in preclinical models.

4. Key Results

A. Functional Redundancy and Essentiality

• Proliferation: Dual inhibition of YES/SRC (via siRNA, shRNA, or CRISPR) markedly suppressed MPNST cell proliferation, whereas single knockdowns had variable or modest effects.
• Genetic Evidence: CRISPR/Cas9 editing revealed that while single clones could survive loss of one kinase, no viable clones survived the complete loss of both YES1 and SRC alleles, confirming their redundant essentiality.
• In Vivo Efficacy:
  • Conditional co-depletion of YES/SRC in orthotopic and subcutaneous models completely abolished tumor growth.
  • Dasatinib treatment (5–15 mg/kg) significantly reduced tumor volume (42% reduction at day 15) and prolonged overall survival in xenograft models.

B. Transcriptional Reprogramming (RNA-seq)

• Oncogenic Suppression: YES/SRC depletion led to the downregulation of cell cycle, mitosis, DNA replication, and E2F target genes.
• Pathway Inhibition: Significant negative enrichment of RAS-ERK1/2, PI3K/AKT, mTORC1, MYC, and YAP/TAZ target signatures.
• Immune Reactivation: Unexpectedly, YES/SRC depletion upregulated interferon (IFN) signaling and Antigen Processing and Presentation (APP) pathways. This included increased expression of MHC class I heavy chains, B2M, TAPBP, and CALR.

C. Proteomic Mechanisms (Phosphoproteomics)

• Signaling Network: Inhibition of YES/SRC caused dephosphorylation of key adaptors (CRK, CRKL) and downstream kinases (ERK2, JNK2, p38), uncoupling receptor tyrosine kinases from mitogenic MAPK signaling.
• Immune Axis: YES/SRC inhibition led to:
  • Increased STAT1 (Tyr701) phosphorylation.
  • Upregulation of NLRC5 (the master transactivator of MHC class I genes).
  • Increased surface expression of HLA Class I (validated by flow cytometry).
  • Conversely, STAT3 (Tyr705) phosphorylation was reduced.
• Conclusion: YES/SRC activity normally represses the IFN-STAT1-NLRC5 axis, maintaining an "immune-cold" phenotype.

D. Clinical Relevance

• Overexpression: Analysis of a large sarcoma cohort showed YES1 is significantly overexpressed in MPNST compared to benign soft tissue tumors (SRC was not).
• Prognostic Value: High YES1 expression correlates with shorter overall survival in the TCGA sarcoma cohort.
• IHC Validation: YAP/TAZ protein levels were confirmed to be higher in MPNSTs than in benign neurofibromas.

5. Significance and Implications

• Novel Therapeutic Target: The study identifies YES/SRC as actionable targets for MPNST, a disease with few treatment options.
• Dual-Pronged Strategy: Targeting YES/SRC offers a unique "two-for-one" therapeutic benefit:
  1. Direct Anti-Proliferative Effect: By shutting down critical mitogenic pathways (RAS/MAPK, PI3K/AKT, YAP/TAZ).
  2. Immune Priming: By converting "cold" tumors into "hot" tumors via MHC class I upregulation, potentially sensitizing MPNSTs to immune checkpoint inhibitors (ICIs).
• Overcoming Resistance: The redundancy of YES and SRC suggests that single-agent targeting may fail due to compensation; dual inhibition (e.g., via Dasatinib or next-generation selective inhibitors) is required.
• Future Directions: The authors propose combining selective YES/SRC inhibitors with immunotherapies to overcome the immune-evasive nature of MPNSTs, moving beyond the current failure of single-agent dasatinib in unselected sarcoma patients.

In summary, this paper provides a robust mechanistic and preclinical foundation for targeting the YES/SRC axis in MPNST, highlighting its potential to simultaneously halt tumor growth and restore immune surveillance.